Transdermal therapeutic systems (TTS);Transdermale therapeutische systeme (TTS)

Medizinische Monatsschrift fur Pharmazeuten

Volumn 21, Issue 12, 1998, Pages 366-377

  Dittgen, Michael ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CORDIPATCH; GLYCERYL TRINITRATE; MDD NG; MINITRANS; NITROCOR TD; POLY[2,2 (1,4 CYCLOHEXANEDIMETHYLENEDIOXY)TETRAHYDROFURAN]; UNCLASSIFIED DRUG; VENITRIN T;

ANGINA PECTORIS; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG FORMULATION; DRUG TRANSPORT; HUMAN; REVIEW;

EID: 0031673154     PISSN: 03429601     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Chien YW Development of transdermal controlled release drug delivery systems: An overview. In: Kydonieus AF, Berner B, editors. Transdermal delivery of drugs. Boca Raton: CRC press, 1987:81-100.
2. Pflegel P, Dittgen M. Arzneimittel und Organismus (VI) - Transdermale Therapeutische Systeme. Pharmazie 1987;42:799-809.
3. Asmussen B. Transdermal therapeutic systems - actual state and future developments, Methods Find Exp Clin Pharmacol 1991;13: 343-51
4. Dittgen M. Therapeutische Systeme, spezielle Wundauflagen und Adhäsionsverbände. In: Nürnberg E, Surmann P, Hrsg. Methoden, Bd. 5. Berlin: Springer-Verlag, 1991:974-86.
5. Zaffaroni A. Haftverband mit Reservoirschicht zur Aufnahme von systemisch wirksamen Arzneimitteln. Alza Corporation, U.S.A. GERM.P 21 35 533 9.41(DE 2 135 533 C3), 1971.
6. Chandrasekaren SK. Therapeutic system for administering drugs to the skin. Alza Corporation, U.S.A. U.K.81300286.2(EP 0 033 615), 1981.
7. Knoch A, Merkle HP Theorie und Praxis transdermaler Freigabesysteme. Acta Pharm Technol 1985;31:197-209.
8. Wolff M, Cordes G, Rehe A. Transdermale Systeme mit Glyceroltrinitrat im Vergleich. Aufbau, Freisetzung und kutane Aufnahme des Wirkstoffs. Dtsch Apoth Ztg 1987;127,601-9
9. Alza Corporation, U.S.A. Electrotransport a technology whose time has come. Data sheet, 1993.
10. Prausnitz MR, Pliquett U, Langer R, Weaver JC. Rapid temporal control of transdermal drug delivery by electroporation. Pharmaceut Res 1994;11:1834-7.
11. Prausnitz MR. The effects of electric current applied to skin: A review for transdermal drug delivery. Advan Drug Delivery Rev 1996;18: 395-425.
12. Meidan VM, Walmsley AD, Irwin WJ. Phonophoresis - Is it a reality? Int J Pharm 1995;118: 129-49.
13. Simonin JP. On the mechanisms of in vitro and in vivo phonophoresis. J Control Release 1995;33:125-41.
14. Lipkovker LM. Ultrasonic transdermal drug delivery system. Endodermic Medical Tech Comp, U.S.A. World:PCT/US93/09798(WO 94/08655), 1994.
15. Santus GC, Baker RW. Transdermal enhancer patent literature. J Controlled Release 1993;25: 1-20.
16. Karzel K, Liedtke RK. Mechanismen transkutaner Resorption Arzneim-Forsch/Drug Res 1989;39:1487-91.
17. Sitruk-Ware R. Transdermal application of steroid hormones for contraception. J Steroid Biochem Molec Biol 1995,53:247-51.
18. Wertz PW. The nature of the epidermal barrier: Biochemical aspects [Abstract]. Advan Drug Delivery Rev 1996;18:283-94.
19. Fartasch M. The nature of the epidermal barrier: Structural aspects. Advan Drug Delivery Rev 1996;18:273-82.
20. Walker RB, Smith EW. The role of percutaneous penetration enhancers. Advan Drug Delivery Rev 1996;18:295-301.
21. Ghosh TK, Banga AK. Methods of enhancement of transdermal drug delivery: Part II A, Chemical permeation enhancers. Pharm Technol Eur 1993;5:62-86.
22. Williams AC, Barry BW. Skin absorption enhancers. CRC 1992;9:305-53.
23. Noven Pharmaceuticals. I. Transdermal device containing polyvinylpyrrolidone as solubility enhancer. Noven Pharmac.Inc., U.S.A. World: PCT/US95/00022(WO 95/18603), 1995.
24. Alza Corporation, U.S.A. Transdermal Technology. Data sheet, 7/13, 1994.
25. Weintraub M, Evans P. Transdermal estradiol: Technology and theory integrated for patient care. Hosp Formul 1986;21:1001-6.
26. Zesch A. Verträglichkeitsaspekte von Transdermalsystemen. Arzneim-Forsch/Drug Res 1989;39:1497-500.
27. Zesch A. Verträglichkeitsaspekte von Transdermalsystemen aus dermatologischer Sicht. Arzneim-Forsch/Drug Res 1989;39:1497-500.
28. Kobler K. Nebenwirkungen von Arzneimittel-Pflastern, Pharma-kritik 1993;15:21-4.
29. Rote Liste Win 1997/II. Aulendorf: ECV Editio Cantor.
30. DMello A. Transdermal patch drug delivery. scrip 1995.
31. Hadgraft J. Pharmaceutical aspects of transdermal nitroglycerin. Int J Pharm 1996;135: 1-11.
32. Man M, Chang C, Lee PH, Broman T, et al. New improved paddle method for determining the in vitro drug release profiles of transdermal delivery systems. J Control Release 1996;27: 59-68.
33. Monkhouse DC, Huq AS. Transdermal drug delivery - problems and promises, Drug Dev Ind Pharm 1988;14:183-209.
34. Fagerström KO, Säwe U, Tonnesen P. Therapeutic use of nicotine patches: efficacy and safety. J Drug Dev 1993;5:191-205.
35. Ho H, Chien YW. Kinetic evaluation of transdermal nicotine delivery systems. Drug Dev Ind Pharm 1993;19:295-313.
36. Lin SS, Chien YW, Huang WC, Li CH, et al. Transdermal nicotine delivery systems: Multi-institutional cooperative bioequivalence studies. Drug Dev Ind Pharm 1993;19:2765-93.
37. De Mey C, Enterling D, Ederhof M, Wesche H, et al. Transdermal delivery of mepindolol and propranolol in normal man. 1st Comm.: Study design, clinical and pharmacodynamic aspects. Arzneim-Forsch/Drug Res 1989;39: 1505-8.
38. De Mey C, Meineke I, Enterling D, Rehbock C, et al. Transdermal delivery of mepindolol and propranolol in normal man. 2nd Comm.: Pharmacokinetic and neuro-endocrine aspects. Arzneim-Forsch/Drug Res 1989;39: 1508-12.
39. Liedtke RK, Chen LS, Mangold B, Haase W. Humanpharmakologische Untersuchungen zur transdermalen Anwendung von Mepindolol. Arzneim-Forsch/Drug Res 1989;39:1501-4.
40. Chlang CM, Tenzel RA. Solid matrix system for transdermal drug delivery. Cygnus Research Company, U.S.A. EU:90309608.9 (EP 0 416 842 A1), 1990.
41. Wick SM. Developing a drug-in adhesive design for transdermal drug delivery Adhesives Age 1995:1-6.
42. Delivery. An update from 3M Pharmaceuticals/Drug Delivery Systems: 7-day estrogen patch launched in the U.S. 5, 1995.
43. Guichard JP, Sauron R, Dutertre JP, Tanner T, et al. A pilot study of the comparative bioavailability of estradiol from two different estradiol transdermal systems: Oeslim 50 and Systen 50. Curr Therap Res 1995;56: 1022-32.
44. Sitruk-Ware R. Transdermal delivery of steroids. Contraception 1989;39:1-20.
45. Place VA, Nichols KC. Transdermal delivery of testosterone with TESTODERM to provide a normal circadian pattern of testosterone. Ann N Y Acad Sci 1991;618:441-9.
46. Cofrancescco JJ, Dobs AS. Transdermal testosterone delivery systems. Endocrinologist 1996;6.207-13.
47. Meikle AW, Arver S, Dobs AS, Sanders SW, et al. Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: Influence of application site - A clinical research center study. J Clin Endocrin Metabol 1996;81: 1832-40.
48. Sanders SW. Transition from temporal to biological control in the clinical development of controlled drug delivery systems. J Controlled Release 1996;39:389-97.
49. Chien TY, Wu SJ, Gong SJ, Chien YW. Transdermal contraceptive delivery system: preclinical development and clinical assessment. Drug Dev Ind Pharm 1994;20:633-64.
50. Inamori T, Ghanem AH, Higuchi WI. Srinivasan V. Macromolecule transport in and effective pore size of ethanol pretreated human epidermal membrane. Int J Pharm 1994;105: 113-23
51. Yamane MA, Williams AC, Barry BW. Effects of terpenes and oleic acid as skin penetration enhancers towards 5-fluorouracil as assessed with time; Permeation, partitioning and differential scanning calorimetry. Int J Pharm 1995;116:237-51.
52. Yamane MA, Williams AC, Barry BW. Terpene penetration enhancers in propylene glycol water co-solvent systems: Effectiveness and mechanism of action. J Pharm Pharmacol 1995;47:978-89.
53. Jenner J, Saleem A, Swanston D. Transdermal delivery of physostigmine. A pretreatment against organophosphate poisoning. J Pharm Pharmacol 1995;47:206-12.
54. Shah JC, Kaka I, Tenjarla S, Lau SWJ, et al. Analysis of percutaneous permeation data. 2. Evaluation of the lag time method. Int J Pharm 1994;109:283-90.
55. Walter K, Muller M, Barkworth MF, Nieciecki A, et al. Pharmacokinetics of physostigmine in man following a single application of a transdermal system. Br J Clin Pharmacol 1995;39: 59-63.
56. Kokubo T, Sugibayashi K, Morimoto Y. Interaction between drugs and pressure-sensitive adhesives in transdermal therapeutic systems Pharm Res 1994;11:104-7.
57. Shah AK, Wei G, Lanman RC, Bhargava VO, et al. Percutaneous absorption of ketoprofen from different anatomical sites in man, Pharmaceut Res 1996;13:168-72
58. Roy SD, Manoukian E, Combs D. Absorption of transdermally delivered ketorolac acid in humans J Pharm Sci 1995;84:49-52.
59. Diani ARS, Zaya KL, Brunden MN The penetration enhancer SEPA augments stimulation of scalp hair growth by topical minoxidil in the stumptail macaque. Skin Pharmacol 1995;9: 221-8.
60. SCRIP Nr. 2143, S.22, 5. Juli 1996.